Clinical Trial Update: Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating pyridostigmine to enhance immune activation in HIV patients with inadequate immune response; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Pyridostigmine (pyridostigmine)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-11-14